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Funding: The authors received no specific funding for this Perspective. Provenance: Commissioned; not externally peer reviewed subclassifying BCLC stage B patients into B1, B2, and B3 categories based on degree of intrahepatic tumor burden; second, in differentiating patients with intrahepatic and extrahepatic metastases; and finally, by incorporating the serum biomarker AFP. In the BCLC system, all patients with liver-isolated disease, without metastases or vascular invasion, are grouped together as BCLC stage B [1] . However, differential survival and locoregional treatment allocation for BCLC stage B patients has been demonstrated in several studies [9, 10] . For example, distinguishing whether BCLC stage B patients are within (B2) or beyond (B3) Milan criteria is important when considering liver transplantation. Similarly, recent data suggest prognosis in patients with extrahepatic metastases is worse than those with intrahepatic metastases, so the differentiation in the ITA.LI.CA system, essentially subclassifying the BCLC stage C patients, adds further granularity to estimating prognosis [11] . Finally, AFP is not part of the BCLC staging system but can serve as a surrogate for occult vascular invasion, distant metastases, or aggressive tumor biology. Patients with an AFP > 500 ng/ml have a higher risk of recurrence post-transplant as well as a lower likelihood of response to locoregional therapy [12] . These three important distinctions as compared to the BCLC system likely explain, in part, the higher prognostic accuracy of the ITA.LI.CA staging system in derivation and validation cohorts. Although the model demonstrated good prognostic discrimination among study patients, it should be noted that most patients in both cohorts had good performance status, compensated cirrhosis, and early or intermediate stage tumors. It is unclear if the ITA.LI.CA staging system would perform as well in cohorts with high rates of hepatic decompensation, poor performance status, and/or advanced tumor stage-subgroups that currently account for the majority of HCC patients in several countries, including the United States. Further, very few patients in this study-less than 2% in the derivation cohort and none in the external validation cohortunderwent liver transplantation, a curative therapy for both the tumor and underlying cirrhosis that plays a crucial role in the management of HCC patients.
Potential future steps in further refinement and validation of the ITA.LI.CA staging system include prospectively assigning treatment allocation recommendations to patients in different stages and validation in more contemporary cohorts, in which transplantation or systemic therapies are utilized to a greater extent.
